Conjunctivitis

DENVER – While the coronavirus has been detected on the ocular surface and in conjunctival secretions of COVID-19-positive patients, the virus is unlikely to be transmitted in this manner, according to a presentation at Optometry’s Meeting.

Interim results from a phase 2 study showed that Okogen’s topical OKG-0301 provided a safe and effective dose-dependent antiviral response in patients with acute adenoviral conjunctivitis, according to a poster presented at ARVO.

Pediatricians often face the challenge of diagnostic accuracy in conjunctivitis cases. Compared with the common clinical syndromes of otitis media and pharyngitis, conjunctivitis presents less frequently and does not require systemic antibiotics. Nonetheless, not every single red or pink eye needs antibiotic drops.

Sore eyes represent a significant ocular symptom in patients with COVID-19, according to a study published in BMJ Open Ophthalmology.

Management of ocular surface disorders may be needed for patients who are on dupilumab to treat atopic dermatitis, according to a presentation at the American Academy of Dermatology virtual meeting.

At the end of March, Wu and colleagues published online in JAMA Ophthalmology the first report on 12 cases of conjunctivitis in 38 patients hospitalized with COVID-19 in China’s Hubei province.

SARS-CoV-2, or COVID-19, has proven to be a formidable challenge worldwide.

Coronavirus unlikely to initiate on the ocular surface indicating that contact lens wear good hygiene practice is still a safe form of vision correction, according to results from a recent study published in Clinical and Experimental Optometry.

Aggressive therapies can treat dupilumab-induced ocular surface inflammation and, depending on the severity of the inflammation, can allow a patient to continue use of the dermatologic therapy.

Dextenza demonstrated a statistically significant mean change in ocular itching scores from baseline in patients with allergic conjunctivitis, according to a press release from Ocular Therapeutix.